The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...
Please provide your email address to receive an email when new articles are posted on . Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open ...
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms ...
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Satralizumab significantly reduces relapse risk in patients with relapsing MOGAD, according to phase 3 METEOROID trial results presented at AAN 2026.
- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
SAN DIEGO — Ozanimod was associated with stable or improved cognition in nearly 90% of patients who received the drug for relapsing-remitting multiple sclerosis (RRMS), a new study showed. Results ...
A new method replicated the findings of a previous clinical trial of Tecfidera in people with relapsing-remitting MS, a study ...
TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the Company’s anti-CD20 monoclonal antibody, in ...
Rituximab vs placebo significantly improved the 49-week relapse-free rate in adults with frequently relapsing or steroid-dependent adult-onset nephrotic syndrome. Adverse events were more common in ...
According to IQVIA data, the approved drug has an estimated market size of $145 million for the 12 months ended December 2025 ...
The test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results